Aurelian Life Sciences Platform
Capital-Efficient Orphan Drug Bridge Platform.
Leveraging the Catalyst/Harmony Model - Keeping what worked and solved what didn’t.
We are building the highest risk-adjusted return model in biopharma
Exclusive focus on Tier 0 assets (approved ex-US or fixable CRL) → 75–80% LoA
• Selective Tier 1 opportunities (late Phase 2 breakthrough data, deprioritized) for follow-on deals
• Low upfront + milestone-heavy deals → keep 75–82% US economics
• First Tier 0 asset closing Q1–Q2 2026 → NDA 2028 → launch 2028–2029 → $300–600M annual run-rate within 4 years
Proven Model = Highest Risk-Adjusted Return in Biopharma
Median return 2018–2025: 22×
Inquiries & Questions ?
Connect With Us Below